ICON audit finds overstated revenue; Secretome and Psilera raise cashnews2026-05-28T14:51:09+00:00May 28th, 2026|Endpoints News|
#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next projectnews2026-05-28T14:47:43+00:00May 28th, 2026|Endpoints News|
Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharmnews2026-05-28T13:54:21+00:00May 28th, 2026|Endpoints News|
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapynews2026-05-28T13:38:47+00:00May 28th, 2026|Endpoints News|
China gene editing startup YolTech raises $70M to move CRISPR therapies forwardnews2026-05-28T12:30:25+00:00May 28th, 2026|Endpoints News|
Oura pushes deeper into healthcare services as part of new ring launchnews2026-05-28T12:00:07+00:00May 28th, 2026|Endpoints News|
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchasenews2026-05-28T11:20:41+00:00May 28th, 2026|Endpoints News|
GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionisnews2026-05-28T08:30:26+00:00May 28th, 2026|Endpoints News|
AstraZeneca’s breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wavenews2026-05-27T15:33:06+00:00May 27th, 2026|Endpoints News|
Apogee secures Blackstone capital to move Dupixent rival into Phase 3news2026-05-27T15:07:51+00:00May 27th, 2026|Endpoints News|
